Upregulation of MYC expression upon either everolimus resistance or acute everolimus treatment was shown to be mediated by its increased association with BRD4 (Bromodomain-containing protein 4), which is clinically associated with multiple types of cancer by transcriptionally and epigenetically regulating key oncogenic drivers [181]. This evidence concerns the gene BRD4 and cancer.